DD284585A5 - METHOD FOR THE PRODUCTION OF MEDICINAL FEEDSTUFFS - Google Patents

Abstract

The invention relates to a process for the preparation of non-antibiotic medicinal feeds which are suitable for combating pathogen-related gastric and intestinal diseases, in particular of colic serotoxaemias in suckling and weanling piglets. According to the invention, a standardized compound feed for lactating sows is supplemented with 50 to 150 mg of a derivative of the formula I per kilogram of finished feed, for example by spraying the active ingredient solution into the feed with constant stirring. By administering these medicated feeds to lactating sows, an increase in the body mass gain of the suckling piglets, an improvement in their general state of health and the reduction of suckling pig losses in pork rearing can be achieved via the sow milk intake. Formula I {medicated feed; * Stomach and intestinal disease; Kolienterotoxaemie; Pig rearing}

Description

The invention relates to a process for the preparation of non-antibiotic medicinal feeds, which are suitable for controlling pathogen-related gastric and intestinal diseases, in particular of colic myotoxia in suckling and heifer piglets. By administering these medicinal products to lactating sows, an increase in the body mass gain of the suckling piglets, an improvement in their general health and the reduction of suckling pig losses in pork rearing can be achieved through sow milk intake.

Characteristic of the known state of the art

It is known to mix derivatives from the group of quinoxaline-1,4-di-N-oxides the compound feed for juveniles and fattening animals for the purpose of stabilizing or improving the state of health, the increase in body mass gain and to improve the feed efficiency. The active ingredients are fed in a multi-stage mixing process over Wirkstoffpraemixe and Wirkstoffvormischungon the specific for a particular species, age group and direction of use compound feed and taken orally in a fixed dosage of the target species.

In pig rearing, derivatives of the quinoxaline-1,4-di-N-oxide group are administered at the start of compound feeding by the piglets from around the age of 5 to 6 weeks of age.

The administration of funds with health-stabilizing effects is of particular importance in the phase of weaning of the piglets from the mother sow, that is, in the transition from the milk diet to the intake of solid food. In this period takes place by changing the milieu in the gastrointestinal tract

a strong proliferation of pathogenic Escherichia coli bacteria, which can lead to colic myotoxemia, a gastrointestinal disease in weaner piglets with "high animal loss rate.

By feeding derivatives to the group of the quinoxaline-1,4-di-N-oxides, in addition to the ergotropic effect, the multiplication of these pathogenic coli bacteria, in particular of the aggressive serotypes, is also counteracted and thereby a health stabilization or improvement can be achieved.

Since the administration of the active substances to the compound feed intake is bound by the forks, an effective influencing of the gastrointestinal flora can take place only after weaning and with sufficient feed intake by the piglets, that is, the critical time of the drastic multiplication of pathogenic Escherichia coli. Germs coincides with the initial uptake of the drug or is delayed in unfavorable cases. This results in the practice of piglet rearing a not always satisfactory health of the weaner piglets.

The currently common procedure for occurring gastric and intestinal diseases consists in a drastic chemotherapy, especially by administering antibiotics. The disadvantage here is the promotion of the spread of a chemotherapeutic resistance, the development of systematic side effects in livestock and the residue problem, In addition, this treatment is also costly.

In order to counteract an increase of pathogenic germs even before weaning and to influence nutritional disturbances occurring in this period and to prepare the critical phase of weaning from the dam, the inclusion of ergotropic agents with health-stabilizing effects in effective concentration would already be required by the suckling pig, which is practically so far was not possible, since food intake in this section is almost exclusively via the sow's milk.

Object of the invention

The aim of the invention is to achieve an increase in body mass gain effective protection of the suckling pig from pathogen-related gastric and intestinal diseases and thus exclude large losses in piglet rearing.

Explanation of the essence of the invention

The object of the invention is to develop a process for the production of ergotically acting medicated feeds without the use of antibiotic Darmflorastabilisatoren, with an ergotrope supply of suckling pig from the first day of life is made possible and can be used to combat pathogen-related gastric and intestinal diseases.

According to the invention this object is achieved by a standardized compound feed for lactating sows with 50 to 150 mg of a derivative of the quinoxaline-l, 4-di-N-oxide of the general formula I,

in the

R is hydrogen, an alkyl or substituted alkyl radical

and R is hydrogen, an alkyl, substituted alkyl or

is a hydroxyethyl carbamoyl radical,

in which

1 2 R and R may be the same or different from each other,

supplemented per kilogram of ready-to-feed.

Surprisingly, it has been found that a dissemination of the quinoxaline · 1,4-di-N-oxide derivatives, depending on the amount of active ingredient fed to the mother animal, takes place via the sow's milk to the suckling piglets.

The example of the active ingredient N- (2-hydroxyethyl) -3-methyl-2-quinoxalinecarboxamide 1-dioxide (Olaquindox) demonstrates this dependence in Table 1:

Tab. 1:

Olaquindox concentration in the sow mixed feed

(Mg / g)

Olaquindox concentration in sour milk

50 100 150

0.17 0.30 0.41

For this purpose, the active ingredient according to the invention was finely incorporated into conventional feed bases. This can take place, for example, by spraying a solution of active substance into the feed with constant stirring or by binding the active ingredient to a feed component, such as cereals, which is then brought into uniform distribution with the compound feed, for example by means of a chargitter.

This disclosure could not be foreseen, since it is known that in the organism of the pig by the so-called blood-milk barrier, a frequently desired transfer of certain drugs from the mother to the piglet is prevented.

In contrast, in the case of the quinoxaline-1-di-N-oxide derivative, as shown in Table 1 by the example of Olaquindox active substance, a dose-dependent transfer of the active substance taken up by the mother orally with the feed over the sow's milk is present the piglet possible.

This makes it possible, already from the first day of life over the entire suckling period in the piglet an ergotrophic supply with repression of pathogenic germs, in particular of Escherichia coli to cause. There is thus an early adaptation of the piglet organism to the supply of active ingredients, which has an advantageous effect on the daily gains in body mass and on piglet morbidity and mortality in comparison to untreated suckling piglets, as is apparent from Table 2.

Tab. 2:

Group of mother sows with suckling piglets

Olaquindox colic content Morbidity mortality

Inclusion of Frischkot rate _____________ ^

Sowing of the piglets / cattle, total including / day

in the compound feed / number d.Keime / days / litter / stomach / intestinal wax in g / ²

Live weight

/ Mg / kg /

illness.

Group I

72 lactating sows with 750 piglets

1.9x10 '

9.2

20

167

Group II

80 lactating sows with 853 piglets

60

1.2 * 10 ^c

6.7

183

Number of stance days / litter requiring medical treatment as a result of illness.

2 Average daily increase over a retention period of 32 days.

The use of the medicinal feed produced according to the invention substantially promotes the welfare of the animals, largely prevents the occurrence of pathogen-related gastric and intestinal diseases or significantly reduces the course of disease and significantly reduces animal losses.

Another advantage of using these medicated feeds is that after discontinuation of its application, the ergotrophic effect and the good growth of the animals persist over a longer period of time.

Claims (1)

claims 1. A process for the preparation of medicated feeds, which are suitable for controlling pathogen-related gastric and intestinal diseases, in particular of colic myotoxia in suckler and heifer piglets, characterized in that a standardized compound feed for lactating sows with 50 to 150 mg of a derivative of quinoxaline -1,4-di-N-oxide of the general formula I, in the R is hydrogen, an alkyl or substituted alkyl radical and
R is hydrogen, an alkyl, substituted alkyl or is a hydroxyethyl carbamoyl radical, wherein 1 2
R and R may be the same or different from each other, Supplemented per kilogram of ready-made food. Method according to claim 1, characterized in that
the supplementation is carried out by spraying the active substance solution into the feed with constant stirring. Method according to claim 1, characterized in that
the supplementation is carried out by binding of the active ingredient to a feed component and this is then brought into even distribution with the compound feed.